Warfarin (Coumadin) + Rivaroxaban (Xarelto, BAY59-7939) + Placebo + Vitamin K (Konakion)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis
Trial Timeline
Nov 1, 2008 → Nov 1, 2009
NCT ID
NCT01507051About Warfarin (Coumadin) + Rivaroxaban (Xarelto, BAY59-7939) + Placebo + Vitamin K (Konakion)
Warfarin (Coumadin) + Rivaroxaban (Xarelto, BAY59-7939) + Placebo + Vitamin K (Konakion) is a phase 1 stage product being developed by Johnson & Johnson for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01507051. Target conditions include Venous Thrombosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01507051 | Phase 1 | Completed |
Competing Products
20 competing products in Venous Thrombosis